Mindpeak’s AI Comes out on Top in Comparative Study on HER2-low Scoring by Cypath and Institut Gustave Roussy

In a first of its kind comparative study, Mindpeak’s CE-marked HER2 AI for breast cancer diagnosis was compared to three other commercial AIs (e.g. Visiopharm). Mindpeak’s AI showed the highest accuracy of all AIs in terms of balanced clinical scores (88.1%) for HER2-low, higher than the score of the next best AI (67.3%) and higher than the concordance of pathologists with the reference score (85.5%). Furthermore, Mindpeak’s AI received the highest scores in a usability evaluation of the AI softwares in all categories.

AiThority Interview Insights: AiThority Interview with Brad Anderson, President of Product and Engineering at Qualtrics

This study was conducted by Cypath-RB together with Institut Gustave Roussy and was presented at the world’s leading annual meeting for pathology, the USCAP 2023 (United States and Canadian Academy of Pathology), in New Orleans in mid-March. 197 tissue samples from breast cancer patients were examined. The study was sponsored by AstraZeneca. Vidal T et al. (2023) USCAP poster board #24, abstract ID 984

Read More about AiThority Interview: AiThority Interview with Ajay Sathyanath, Chief Technology Officer at Madison Logic

Breast cancer is the most common cancer in women and accounts for about one third of all malignancies in women. Breast cancer forms metastases at an increased rate and has so far resulted in a high mortality rate. Early detection of this disease leads to improved treatment outcomes and significantly higher survival rates. The use of molecular biomarkers ensures that breast cancer patients receive more and more targeted treatment. Biomarkers such as HER2 play a central role in predicting prognosis and determining individual therapy. More than half of metastasized breast cancers express low levels of HER2, traditionally associated with poor outcome. Recent clinical studies have shown the efficacy treatment (Enhertu, AstraZeneca) in this patient group with significant clinical benefit compared to standard-of-care treatment.

Mindpeak is Europe’s leading provider of AI software for pathology. Over 10,000 patients have been diagnosed with the help of Mindpeak’s AI. With a focus on tissue biomarker analysis and discovery, Mindpeak serves clinical laboratories and biopharma companies around the world. Mindpeak’s AI-algorithms were the first to be used in routine clinical diagnostics in the US and EU.

 Latest AiThority Interview Insights : AiThority Interview with at Brian Sathianathan, Co-Founder and CTO at Iterate.ai

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Mindpeak’s AI Comes out on Top in Comparative Study on HER2-low Scoring by Cypath and Institut Gustave Roussy appeared first on AiThority.

diagnostics
biomarkers